regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Active Pharmaceutical Ingredients (APIs), the most common co-covered peer. Their average consequence score of 8 runs above the beat's 5.9 for that window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about House Select Committee on China
regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Active Pharmaceutical Ingredients (APIs), the most common co-covered peer. Their average consequence score of 8 runs above the beat's 5.9 for that window. Source depth averages 3 original sources per story, versus 3 across the same-window beat baseline. House Select Committee on China appears in 1 tracked Healthcare story from March 19, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering House Select Committee on China. Shared-story counts are live from our verified record — not editorial picks.
A high-profile House Select Committee hearing has highlighted the United States' critical dependence on Chinese active pharmaceutical ingredients (APIs). Lawmakers warn that Beijing is applying its successful industrial playbook from rare earths and EVs to corner the global medicine market, with Chinese pharma revenue projected to hit $2.1 trillion by 2030.
House Select Committee on China is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.